MA-ECHOSENS
21.6.2022 14:58:10 CEST | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce its solutions will be included in 22 oral presentations and 157 posters that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings at EASL International Liver Congress™ 2022, June 22-26, 2022, London, United Kingdom. Echosens leaders will present the symposium “FibroScan® Solutions Bringing New Guidelines to Life,” 11 a.m.-12:30 p.m., Meeting Room N19, ExCel London Center, on June 23. Additionally, Echosens will offer “How to Improve Early Screening and Management of Chronic Liver Disease Outside Hospital Setting?” -- two demonstrations of FibroScan® GO, 3 p.m.-4 p.m. or 5:30 p.m.-6:30 p.m. on June 23 in Meeting Room N19, ExCel London.
“This very important meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology,” says Dominique Legros, Group CEO, Echosens. “FibroScan® , the non-invasive solution for comprehensive management of liver health, is recognized worldwide, validated by over 3,500 peer reviewed publications and 160 international guidelines and considered the most widely studied tool for point of care liver assessment.”
Echosens will be available at booth N°46 to discuss and demonstrate early detection with new FibroScan GO, diagnosing and monitoring with FibroScan Mini+ 430 and FibroScan Compact 530, advanced diagnosis and risk stratification with FibroScan Expert 630 live patient demonstration, and digital demonstrations of myFibroScan and Scores by Echosens.
Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the global validation of FibroScan and broad consensus of the need for screening and early intervention to prevent advanced liver disease. FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage, as well as provide metrics for monitoring changes in liver fat due to lifestyle modification.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005114/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SamanTree Medical’s Histolog® Scanner Technology Featured in 13 Publications in Special BJU International Issue on Confocal Microscopy in Urology1.7.2026 15:01:00 CEST | Press release
Papers highlight clinical research on use of confocal microscopy for real-time tissue assessment in various urologic procedures SamanTree Medical, a global leader in surgical imaging innovation, today announced that Histolog Scanner confocal microscopy technology has been featured in 13 peer-reviewed clinical papers in a special issue of BJU International, one of the world’s leading journals in urology. The special edition focuses on a growing body of evidence of the role of confocal microscopy in urologic surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701425845/en/ SamanTree Medical announces that Histolog® Scanner confocal microscopy technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International. “The special issue represents increasing momentum behind confocal microscopy in urologic surgery,” said Professor Greg Shaw, consultant urologic surgeon at University College London
Regnology to Acquire Fed Reporter, Accelerating U.S. Leadership and Advancing Regulatory Modernization1.7.2026 15:00:00 CEST | Press release
Deal establishes Regnology as a central partner in U.S. regulatory modernization, extending reach to over 4,000 financial institutions Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced it has entered into a definitive agreement to acquire Fed Reporter, the market-leading U.S. provider of regulatory reporting solutions for financial institutions of all sizes, including banks, credit unions, and bank holding companies. The acquisition marks a pivotal milestone in Regnology’s U.S. expansion, creating the most comprehensive regulatory reporting coverage across the American financial landscape and extending its reach to more than 4,000 institutions from global banks to community lenders. By combining a proven, cloud-first, agentic-first technology foundation with deeply embedded local expertise, Regnology is uniquely positioned to support more efficient, transparent, and data-driven reporting, while strengthening alignment bet
Xsolla Announces Scholarship Program to Support Emerging Developers1.7.2026 15:00:00 CEST | Press release
New Initiative Expands Access To Gamescom By Reducing Financial Barriers For Independent And Mid-Tier Game Developers Worldwide Xsolla, a leading global video game commerce company, today announced the launch of the Xsolla Developer Scholarship Program - Cologne 2026 an initiative designed to support independent and mid-tier game developers who face financial barriers to attending gamescom 2026 in Cologne, Germany. As the world’s largest gaming event, gamescom brings together developers, publishers, investors, and industry leaders from across the globe to explore new opportunities, showcase innovative projects, and build meaningful business relationships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701200418/en/ Graphic: Xsolla The developer scholarship program is designed to help promising studios and independent creators gain access to one of the industry’s most influential events by providing professional developmen
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program1.7.2026 13:55:00 CEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule API and HPAPI, announced today that AGC has successfully completed an onsite assessment of its new Barcelona facility using the VERIF.i® supplier pre-assessment program. The newly expanded Barcelona site strengthens AGC’s position as a global leader in the development and commercialization of complex small molecule Active Pharmaceutical Ingredients (APIs) and highly potent APIs (HPAPIs). Designed for maximum flexibility, safety, and energy efficiency, the facility expands AGC’s end-to-end capabilities from gram-scale to ton-scale production under the highest quality and sustainability standards. “At AGC Pharma Chemicals, we place the highest priority on the integrity of our operational processes and the expertise of our frontline teams,” said Jun Kurihar
Introducing Arbex: a New Global Leader in Tissue and Hygiene1.7.2026 13:37:00 CEST | Press release
$3.4 billion joint venture between Suzano and Kimberly-Clark launches independent operations and reveals key corporate details Upon launch, Arbex becomes one of the world’s largest tissue and hygiene businesses, operating across more than 70 markets on five continents, with its headquarters in the Netherlands and an operational office in London. The company will produce and sell leading global and regional brands including Kleenex®, Scott®, Cottonelle®, Andrex®, and Viva®, with 22 manufacturing sites in 14 countries. Ehab Abou-Oaf, previously President of International Family Care & Professional at Kimberly-Clark, will directly transition in as Arbex’s CEO, with the role to be based in the United Kingdom alongside the majority of the global executive team. Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom